Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 3
1(16.7%)
6Total
N/A(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00826059Not ApplicableCompleted

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Role: lead

NCT04014621Not ApplicableUnknown

Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial

Role: lead

NCT03733236Not ApplicableCompleted

Safety and Effectiveness Evaluation of the ISS System in Treatment of Acute Ischemic Stroke

Role: lead

NCT03551093Not ApplicableCompleted

THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset)

Role: lead

NCT03396419Terminated

IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)

Role: lead

NCT03767192Not ApplicableTerminated

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)

Role: lead

NCT01874093Phase 3Terminated

IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset

Role: lead

All 7 trials loaded